chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Influenza like illness, Pain, Pyrexia, Vaccination site pain
Clinical narrative: Flu-like symptons; 101 Fever; Chills; body ache; fatigue; headache; Arm injection site extremely sore; Arm injection site extremely sore, to the point of arm immobility; This is a spontaneous report from a non-contactable consumer, the patient. A 42-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE BIONTECH, Lot number: EN6204) via an unspecified route of administration in the right arm on 20Mar2021 at 13:15 (at the age of 42-years-old), as a single dose for COVID-19 immunisation. The patient had no medical history. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6205), via an unspecified route of administration in the right arm on 27Feb201 at 18:30 (at the age of 42-years-old), as a single dose for COVID-19 immunisation. The patient did not have any allergies to food, medications, or other products. Concomitant medication was not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient had not been diagnosed with COVID-19. Since the vaccination, it was unknown if the patient had been tested for COVID-19. On 20Mar2021, after 5 hours of second shot, patient experienced arm injection site extremely sore, to the point of arm immobility. On 21Mar2021, the patient experienced flu-like symptoms the day after second shot, 101 fever, chills, body aches, fatigue, headache. The patient underwent lab tests and procedures which included body temperature and result was 101 fever (units not specified). The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Treatment was not received as a result of reported events. The clinical outcome of flu-like symptoms, fever, chills, general body pain, fatigue, headache, vaccination site pain and movement reduced (arm immobility) were resolved on an unknown date of Mar2021, at the time of this report. No follow-up attempts are possible. No further information is expected.
Age: 17.0
Sex: F
Vaccine: COVID19
Symptoms: Heart rate, Heart rate increased, Paraesthesia, Vision blurred
Clinical narrative: Blurred Vision; Rapid Heart Rate; Tingling in extremities; This is a spontaneous report from a contactable healthcare professional. A 17-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8734), via intramuscular route in the right arm on 26Mar2021 at 09:45 (at the age of 17-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. It was unknown if the patient had been tested for COVID-19 since the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6206), via intramuscular route in the right arm on 05Mar2021 at 12:00 (at the age of 17-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 26Mar2021 at 09:45, the patient experienced tingling in extremities, blurred vision, and rapid heart rate. The adverse events resulted in emergency room/department or urgent care. It was unknown if the patient had received any treatment for the events tingling in extremities, blurred vision, and rapid heart rate. The clinical outcomes of the events tingling in extremities, blurred vision, and rapid heart rate were unknown at the time of the report.   No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Fatigue, Malaise, Pyrexia
Clinical narrative: Chills; Slight temperature; Feeling very wiped out tired; feeling not well; This is a spontaneous report from a contactable healthcare professional, the patient. A 56-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP7534), via an unspecified route of administration in the right arm on 18Mar2021 at 16:00 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure and the patient was on medication for it. The patient did not have any allergies to medications, food or other products. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medication included unspecified medication for high blood pressure from an unknown date. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 21Mar2021 at 22:00, approximately three days after the vaccination, the patient started feeling not well. On 25Mar2021, seven days after the dose, the patient woke up to chills, slight temperature and feeling very wiped out tired. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events feeling not well, chills, slight temperature and feeling very wiped out tired. The clinical outcomes of the events feeling not well, chills, slight temperature and feeling very wiped out tired were not recovered at the time of the report.   No follow-up attempts are needed. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Asthma, Pruritus
Clinical narrative: Mild asthma triggered; Extremely itchy skin; This is a spontaneous report from a contactable consumer, the patient and contactable health care professional. A 42-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via unspecified route of administration on right arm on 25Mar2021 at 04:45 (at the age of 42-year-old) as a single dose, for COVID-19 immunisation. Medical history included asthma, chronic fatigue disorder and anemia. The patient had allergy to naproxen sodium (ALEVE). Concomitant medications included lamotrigine (LAMICTAL), bupropion hydrochloride (WELLBUTRIN), cetirizine hydrochloride (ZYRTEC), Montelukast sodium (SINGULAIR) and liraglutide (SAXENDA). The patient did not receive any other vaccine in four weeks prior to COVID vaccine. The patient was not diagnosed with COVID-19 prior to vaccination. Since the vaccination, the patient had not tested for COVID-19. The patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via unspecified route of administration on left arm on 05Mar2021 at 04:45 (at the age of 41-year-old) as a single dose, for COVID-19 immunisation. On 25Mar2021 at 22:00, the patient had mild asthma triggered (just needed her inhaler) and extremely itchy skin. The patient had not received any treatment for the reported events. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of events mild asthma triggered and extremely itchy skin were unknown at the time of this report.  Information about lot/batch number cannot be obtained. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain upper
Clinical narrative: Acute stomach pain; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6199) via an unspecified route of administration in the right arm on 23Mar2021 at 13:00 (at the age of 50-years-old) as a single dose, for COVID-19 immunisation. Medical history included hypothyroidism, celiac disease, and asthma. The patient did not have any known allergies. The concomitant medication included levothyroxine sodium (SYNTHROID) for an unknown indication. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN5318) via an unspecified route of administration in the right arm on 02Mar2021 at 13:00 (at the age of 50-years-old) as a single dose, for COVID-19 immunisation. The patient did not receive any other vaccine within 4 weeks prior to the vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On 25Mar2021 at 12:00 (two days after vaccine), the patient experienced acute stomach pain that lasted for several hours. The patient did not receive any treatment for the reported event. The adverse events resulted in emergency room/department or urgent care visit. The clinical outcome of the event acute stomach pain was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Urticaria, Vaccination site bruising, Vomiting
Clinical narrative: Bruised injection site; Headache; Vomiting; Hives all over face; This is a spontaneous report from a contactable consumer, the patient. A 25-year-old non-pregnant female patient received the second dose BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN), via an unspecified route of administration in the left arm on 25Mar2021 at 11:00 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history reported. The patient did not have any allergies to food, medications, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any concomitant medications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 04Mar2021 at 11:00 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 25Mar2021 at 13:00, the patient experienced headache, vomiting, bruised injection site and hives all over face. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events headache, vomiting, bruised injection site and hives all over face. The clinical outcomes of the events headache, vomiting, bruised injection site and hives all over face were recovering at the time of the report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Pain, Pyrexia, Vomiting
Clinical narrative: Chills; body aches; low grade fever; vomiting; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EK8730) via an unspecified route of administration in the left arm on 24Mar2021 at 02:45 (at the age of 41-year-old), as a single dose for COVID-19 immunisation. The patient's medical history included COVID-19. The patient did not have allergic to medications, food, or other products. Concomitant medication was not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 25Mar2021 at 10:00, patient experienced chills, body aches, low grade fever and vomiting. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment received for the adverse events. The clinical outcome of the events chills, body aches, low grade fever and vomiting was resolving at the time of this report. No follow-up attempts are needed. No further information is expected.
Age: 17.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Pain
Clinical narrative: Fatigue; chills; achy; This is a spontaneous report from a contactable consumer, the parent. A 17-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP6955) via an unspecified route of administration in the left arm on 19Mar2021 at 09:00 (at the age of 17-years-old) as a single dose for COVID-19 immunisation. Medical history included depression and allergy to (ZOFRAN). Prior to vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included multi-vitamins (unspecified). The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Since the vaccination, the patient had not been tested for COVID-19. On 20Mar2021 at 08:00, the patient experienced fever, chills and achy. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported events. The clinical outcome of the events fever, chills and achy were resolved on an unknown date.   No follow-up attempts are needed. No further information is expected.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Diarrhoea, Fatigue, Headache
Clinical narrative: significant joint pain; fever; chills; headache; swelling and soreness at injection site; swelling and soreness at injection site; facial rash; an hour of diarrhea; Onset of extreme fatigue; This is a spontaneous report from a contactable nurse. A 57-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955), via an unspecified route of administration in the left arm on 23Mar2021 at 15:15 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. Medical history of patient included asthma, diastolic heart failure, CKD (chronic kidney disease) stage 2; all from unknown duration. The patient was intubated and ventilated at time of COVID-19 infection in Nov2020. The patient did not had allergy to any medications, food, or other products. The patient previously received first dose of BNT162b2(PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6203), via an unspecified route of administration in the left arm on 03Mar2021 at 15:30 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. On 23Mar2021, at 19:15, 20:15 the patient had an onset of extreme fatigue, followed by an hour of diarrhea respectively. On 24Mar2021, the next morning, the patient experienced significant joint pain, fever, chills, headache, swelling, and soreness at injection site and facial rash. Therapeutic measures were taken as a result of adverse events with TYLENOL. The events didn't result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events fatigue extreme, diarrhea, joint pain, fever, chills, headache, vaccination site pain, vaccination site swelling, facial rash were recovered on an unknown date in Mar2021.  No follow-up attempts are needed. No further information is expected.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, Rash, Vaccination site pain, Vaccination site swelling
Clinical narrative: significant joint pain; fever; chills; headache; swelling and soreness at injection site; swelling and soreness at injection site; facial rash; an hour of diarrhea; Onset of extreme fatigue; This is a spontaneous report from a contactable nurse. A 57-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955), via an unspecified route of administration in the left arm on 23Mar2021 at 15:15 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. Medical history of patient included asthma, diastolic heart failure, CKD (chronic kidney disease) stage 2; all from unknown duration. The patient was intubated and ventilated at time of COVID-19 infection in Nov2020. The patient did not had allergy to any medications, food, or other products. The patient previously received first dose of BNT162b2(PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6203), via an unspecified route of administration in the left arm on 03Mar2021 at 15:30 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. On 23Mar2021, at 19:15, 20:15 the patient had an onset of extreme fatigue, followed by an hour of diarrhea respectively. On 24Mar2021, the next morning, the patient experienced significant joint pain, fever, chills, headache, swelling, and soreness at injection site and facial rash. Therapeutic measures were taken as a result of adverse events with TYLENOL. The events didn't result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events fatigue extreme, diarrhea, joint pain, fever, chills, headache, vaccination site pain, vaccination site swelling, facial rash were recovered on an unknown date in Mar2021.  No follow-up attempts are needed. No further information is expected.
Age: 19.0
Sex: M
Vaccine: COVID19
Symptoms: Urticaria
Clinical narrative: Hives over upper body and back of neck. It then spread to lower body, forearms, and forehead; This is a spontaneous report received from a contactable consumer, the patient. A 19-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EP6955) via an unspecified route of administration in the left arm on 23Mar2021 at 13:30 (at the age of 19-years-old) as a single dose for COVID-19 immunisation. The medical history included myopia and astigmatism. The concomitant medications were not reported. The patient had no known allergies. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. On 24Mar2021 at 21:00 the patient developed hives. The patient reported that he developed hives over upper body and back of neck which started 32 hours after vaccination around 21:00 and it subsided a little after he went to bed. It then spread to lower body, forearms and forehead at 20:00 on 25Mar2021. The hives were nearly gone on the morning of 26Mar2021. At no point did the hives reached his throat or other vital areas to breathing. The patient received BENADRYL, ALLEGRA and PEPCID as treatment for the reported event hives. The adverse event resulted in a visit to the doctors or other healthcare professional office/clinic visit. The clinical outcome of the event hives was resolving at the time of this report.   No follow-up attempts are needed. No further information expected.
Age: 40.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Decreased appetite, Dysarthria, Dyspnoea, Fatigue
Clinical narrative: Increased yawn reflex to find air.; Chills immediately after/ cold body; Sweaty hands; Tight throat muscles; Sore upper left arm; Weird feeling in the body; Very slight difficulty breathing; Very slight difficulty articulating some words; Nausea; Difficulty sleeping; Loss of appetite; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EK8727) via an unspecified route of administration in the left arm on 24Mar2021 at 16:45 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history included anxiety. The patient had known allergies to penicillin and amoxicillin. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medications included omeprazole (MANUFACTURER UNKNOWN) 20mg once a day for unknown indication and from an unknown date. On 24Mar2021 at 16:45, the patient experienced increased yawn reflex to find air, chills immediately after / cold body, sweaty hands, fatigue, tight throat muscles, sore upper left arm, weird feeling in the body, very slight difficulty breathing (but SPO2 ok at 98%), very slight difficulty articulating some words, nausea, difficulty sleeping and loss of appetite. The patient did not receive any treatment for the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient underwent lab tests which included oxygen saturation test on an unknown date and the result was SPO2 at 98%. The clinical outcome of events increased yawn reflex to find air, chills immediately after / cold body, sweaty hands, fatigue, tight throat muscles, sore upper left arm, weird feeling in the body, very slight difficulty breathing, very slight difficulty articulating some words, nausea, difficulty sleeping and loss of appetite was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: M
Vaccine: COVID19
Symptoms: Feeling abnormal, Hyperhidrosis, Insomnia, Nausea, Oxygen saturation
Clinical narrative: Increased yawn reflex to find air.; Chills immediately after/ cold body; Sweaty hands; Tight throat muscles; Sore upper left arm; Weird feeling in the body; Very slight difficulty breathing; Very slight difficulty articulating some words; Nausea; Difficulty sleeping; Loss of appetite; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EK8727) via an unspecified route of administration in the left arm on 24Mar2021 at 16:45 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history included anxiety. The patient had known allergies to penicillin and amoxicillin. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medications included omeprazole (MANUFACTURER UNKNOWN) 20mg once a day for unknown indication and from an unknown date. On 24Mar2021 at 16:45, the patient experienced increased yawn reflex to find air, chills immediately after / cold body, sweaty hands, fatigue, tight throat muscles, sore upper left arm, weird feeling in the body, very slight difficulty breathing (but SPO2 ok at 98%), very slight difficulty articulating some words, nausea, difficulty sleeping and loss of appetite. The patient did not receive any treatment for the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient underwent lab tests which included oxygen saturation test on an unknown date and the result was SPO2 at 98%. The clinical outcome of events increased yawn reflex to find air, chills immediately after / cold body, sweaty hands, fatigue, tight throat muscles, sore upper left arm, weird feeling in the body, very slight difficulty breathing, very slight difficulty articulating some words, nausea, difficulty sleeping and loss of appetite was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: M
Vaccine: COVID19
Symptoms: Pain in extremity, Throat tightness, Yawning
Clinical narrative: Increased yawn reflex to find air.; Chills immediately after/ cold body; Sweaty hands; Tight throat muscles; Sore upper left arm; Weird feeling in the body; Very slight difficulty breathing; Very slight difficulty articulating some words; Nausea; Difficulty sleeping; Loss of appetite; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EK8727) via an unspecified route of administration in the left arm on 24Mar2021 at 16:45 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history included anxiety. The patient had known allergies to penicillin and amoxicillin. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medications included omeprazole (MANUFACTURER UNKNOWN) 20mg once a day for unknown indication and from an unknown date. On 24Mar2021 at 16:45, the patient experienced increased yawn reflex to find air, chills immediately after / cold body, sweaty hands, fatigue, tight throat muscles, sore upper left arm, weird feeling in the body, very slight difficulty breathing (but SPO2 ok at 98%), very slight difficulty articulating some words, nausea, difficulty sleeping and loss of appetite. The patient did not receive any treatment for the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient underwent lab tests which included oxygen saturation test on an unknown date and the result was SPO2 at 98%. The clinical outcome of events increased yawn reflex to find air, chills immediately after / cold body, sweaty hands, fatigue, tight throat muscles, sore upper left arm, weird feeling in the body, very slight difficulty breathing, very slight difficulty articulating some words, nausea, difficulty sleeping and loss of appetite was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Fatigue, Headache, Myalgia
Clinical narrative: Headache; Fever/ 101F; Chills; muscle pain especially in legs; Fatigue; sore arm at injection site; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old non-pregnant female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6199), via unspecified route of administration in the left arm on 16Mar2021 at 10:00 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history and no known allergies to medications, food or other products. Information on concomitant medications was not provided and the patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously received first dose of BNT162B2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, lot number: EN5318) in the left arm on 23Feb2021 at 13:00 (at the age of 33-years-old) as a single dose for COVID-19 immunisation.  Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 16Mar2021 at 22:00 patient experienced headache, 101F fever, chills, muscle pain especially in legs, fatigue and sore arm at injection site. The patient did not receive treatment for the reported events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of headache, 101F fever, chills, muscle pain especially in legs, fatigue and sore arm at injection site was recovered.   No follow-up attempts are needed. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, Vaccination site pain
Clinical narrative: Headache; Fever/ 101F; Chills; muscle pain especially in legs; Fatigue; sore arm at injection site; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old non-pregnant female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6199), via unspecified route of administration in the left arm on 16Mar2021 at 10:00 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history and no known allergies to medications, food or other products. Information on concomitant medications was not provided and the patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously received first dose of BNT162B2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, lot number: EN5318) in the left arm on 23Feb2021 at 13:00 (at the age of 33-years-old) as a single dose for COVID-19 immunisation.  Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 16Mar2021 at 22:00 patient experienced headache, 101F fever, chills, muscle pain especially in legs, fatigue and sore arm at injection site. The patient did not receive treatment for the reported events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of headache, 101F fever, chills, muscle pain especially in legs, fatigue and sore arm at injection site was recovered.   No follow-up attempts are needed. No further information is expected.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Colitis, Psoriasis, Rash, Sensitive skin
Clinical narrative: sensitive skin; psoriasis; colitis; full body rash two days after shot; This is a spontaneous report received from a contactable consumer, the patient. A 58-years-old non-pregnant female patient received her second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6199) via an unspecified route of administration in left arm on 08Mar2021 at 10:00 (at the age of 58 years) as a single dose, for COVID-19 immunisation. Medical history of the patient included colitis, psoriasis and allergies to pecans. Patient previously took immune suppressing drug mercaptopurine, monitored with blood draws, white cell count normal. The patient was not diagnosed with COVID-19 prior to the vaccination and was not tested for COVID-19 since the vaccination. Concomitant medication included unspecified medications. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient experienced full body rash two days after shot, sensitive skin, psoriasis and colitis on 10Mar2021 at 700. Event full body rash two days after shot had resulted in doctor visit on 22Mar2021. Patient took prescription unspecified cream and Benadryl as treatment for reported events. The clinical outcome of events full body rash, sensitive skin, psoriasis and colitis was not recovered at the time of this report.    No follow-up attempts are needed. No further information is expected
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Feeding disorder, Feeling cold, Headache
Clinical narrative: Severe headache; Blurry vision; Feverish; My skin ached; Alternating with chills; Extremely cold; Nauseous; Unable to eat; Exhausted; Slept for about 48 hours; This is a spontaneous report from a contactable consumer, the patient. A 68-year-old non-pregnant female patient received an unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6200), via an unspecified route of administration in the left arm on 24Mar2021 at 13:45 (at the age of 68-years-old), as a single dose for COVID-19 immunisation. Medical history included celiac disease (gluten). Concomitant medication included liothyronine (MANUFACTURER UNKNOWN), statin (MANUFACTURER UNKNOWN) and alprazolam (MANUFACTURER UNKNOWN); all for unspecified indication from unknown dates. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Since the vaccination, the patient had not tested for COVID-19. On 24Mar2021 at 22:00, the patient experienced severe headache, blurry vision, feverish, skin ached, alternating with chills and becoming extremely cold, nauseous and was unable to eat and exhausted. The patient slept for 48 hours and got up only to take TYLENOL and drink liquids. The clinical outcome of the events headache, blurry vision, feverish, skin pain, chills, sensation of cold, nauseous, unable to eat, exhausted and sleep excessive were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Hypersomnia, Nausea, Pain of skin, Pyrexia, Vision blurred
Clinical narrative: Severe headache; Blurry vision; Feverish; My skin ached; Alternating with chills; Extremely cold; Nauseous; Unable to eat; Exhausted; Slept for about 48 hours; This is a spontaneous report from a contactable consumer, the patient. A 68-year-old non-pregnant female patient received an unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6200), via an unspecified route of administration in the left arm on 24Mar2021 at 13:45 (at the age of 68-years-old), as a single dose for COVID-19 immunisation. Medical history included celiac disease (gluten). Concomitant medication included liothyronine (MANUFACTURER UNKNOWN), statin (MANUFACTURER UNKNOWN) and alprazolam (MANUFACTURER UNKNOWN); all for unspecified indication from unknown dates. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Since the vaccination, the patient had not tested for COVID-19. On 24Mar2021 at 22:00, the patient experienced severe headache, blurry vision, feverish, skin ached, alternating with chills and becoming extremely cold, nauseous and was unable to eat and exhausted. The patient slept for 48 hours and got up only to take TYLENOL and drink liquids. The clinical outcome of the events headache, blurry vision, feverish, skin pain, chills, sensation of cold, nauseous, unable to eat, exhausted and sleep excessive were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Headache, Lymphadenopathy
Clinical narrative: Dizziness; Headache; Swollen lymph nodes; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old non-pregnant female patient received an unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 17Mar2021 at 19:00 (at the age of 39-years-old) as single dose for COVID-19 immunisation. No relevant medical history and concomitant medication was reported. The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 24Mar2021 (approximately one week after the vaccine), the patient experienced headache, dizziness and swollen lymph nodes. The patient did not receive any treatment for the events experienced. The adverse events did not result in a doctor or other healthcare professional office/clinic visit/ emergency visit. The clinical outcomes of the events headache, dizziness and swollen lymph nodes were resolving at the time of this report.   Information about lot number cannot be obtained. No further information expected.
Age: 33.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Body temperature, Chills, Myalgia, Pyrexia
Clinical narrative: severe chills for 2 hours (onset 15 hours following administration; aching  joints; fever (~101 F) persisting for approximately 24 hours; aching muscles; very minor pain to the touch at injection site; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old, male patient received second dose of BNTI62b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP6955), via an unspecified route of administration in the left arm on 24Mar2021 at 09:00 (at the age of 33-year-old) as a single dose for COVID-19 immunisation. Patient had no medical history. The patient did not receive any other medication within 2 weeks of vaccination. The patient previously received first dose of BNTI62b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL3248), via an unspecified route of administration in the left arm on 04Mar2021 (at the age of 33-year-old) as a single dose for COVID-19 immunisation. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 25Mar2021, the patient experienced chills, muscles pain, joints pain, fever and vaccination site pain. It was reported that patient had severe chills for ~2 hours (onset 15 hours following administration), fever (101 F) persisting for approximately 24 hours, very minor pain to the touch at injection site. No therapeutic measures were taken as a result of the events. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events of muscle pain, joint pain and vaccination site pain was recovered. The clinical outcome of the events chills was resolved on 25Mar2021 and fever was resolved on 26Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 33.0
Sex: M
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: severe chills for 2 hours (onset 15 hours following administration; aching  joints; fever (~101 F) persisting for approximately 24 hours; aching muscles; very minor pain to the touch at injection site; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old, male patient received second dose of BNTI62b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP6955), via an unspecified route of administration in the left arm on 24Mar2021 at 09:00 (at the age of 33-year-old) as a single dose for COVID-19 immunisation. Patient had no medical history. The patient did not receive any other medication within 2 weeks of vaccination. The patient previously received first dose of BNTI62b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL3248), via an unspecified route of administration in the left arm on 04Mar2021 (at the age of 33-year-old) as a single dose for COVID-19 immunisation. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 25Mar2021, the patient experienced chills, muscles pain, joints pain, fever and vaccination site pain. It was reported that patient had severe chills for ~2 hours (onset 15 hours following administration), fever (101 F) persisting for approximately 24 hours, very minor pain to the touch at injection site. No therapeutic measures were taken as a result of the events. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events of muscle pain, joint pain and vaccination site pain was recovered. The clinical outcome of the events chills was resolved on 25Mar2021 and fever was resolved on 26Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Dyspepsia, Fatigue
Clinical narrative: Fatigue; heartburn; This is a spontaneous report from a contactable consumer, the patient. A 69-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown) via unspecified route of administration in the left arm on 24Mar2021 at 12:30 (at the age of 69-years-old), as a single dose for COVID-19 immunisation. Medical history and concomitant therapy were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown) via unspecified route of administration in the left arm on 03Mar2021 at 12:30, as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. It was unknown that the patient had tested for COVID-19 since having the vaccine. It was unknown that the patient had received any other vaccines within four weeks prior to the COVID-19 vaccine. On the same day of vaccination at 19:30, the patient experienced, fatigue and heartburn. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Treatment received for the events was reported as unknown. The clinical outcomes of the events fatigue and heartburn were recovered on an unknown date in Mar2021.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Nausea, Pain, Peripheral swelling
Clinical narrative: Headache; Fever; chills; Body ache; Nausea; Swollen  armpit; This is a spontaneous report from a contactable consumer, the patient. A 60-years-old non-pregnant female patient received second dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, lot number: EP7534), via an unspecified route of administration in the left arm on 23Mar2021 at 09:30, (At the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure, atrial tachycardia, thyroid disease and Hashimotos disease. Concomitant medications taken within 2 weeks prior to vaccination include Levothyroxine (MANUFRATURER UNKNOWN) and Diltiazem hydrochloride (CARTIA) both for unspecified indications. The patient previously received first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, lot number: EN6203), via an unspecified route of administration in the left arm on 02Mar2021 at 10:00 as a single dose for COVID-19 immunisation. The patient was allergic to codeine and demerol. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. The patient had not received any other vaccines within four weeks prior to the COVID-19 vaccine. On 23Mar2021, the patient experienced headache, fever, chills, body aches, nausea and swollen left armpit. The adverse event had not resulted in doctor or other healthcare professional office/clinic visit/ emergency visit/ department or urgent care. The patient did not take any medication for headache, nausea, chills, fever, swollen arm, general body pain. The clinical outcome of the events headache, nausea, chills, fever, swollen arm, general body pain was recovering at the time of this report.   No follow-up attempts possible. No further information expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Headache; Fever; chills; Body ache; Nausea; Swollen  armpit; This is a spontaneous report from a contactable consumer, the patient. A 60-years-old non-pregnant female patient received second dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, lot number: EP7534), via an unspecified route of administration in the left arm on 23Mar2021 at 09:30, (At the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure, atrial tachycardia, thyroid disease and Hashimotos disease. Concomitant medications taken within 2 weeks prior to vaccination include Levothyroxine (MANUFRATURER UNKNOWN) and Diltiazem hydrochloride (CARTIA) both for unspecified indications. The patient previously received first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, lot number: EN6203), via an unspecified route of administration in the left arm on 02Mar2021 at 10:00 as a single dose for COVID-19 immunisation. The patient was allergic to codeine and demerol. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. The patient had not received any other vaccines within four weeks prior to the COVID-19 vaccine. On 23Mar2021, the patient experienced headache, fever, chills, body aches, nausea and swollen left armpit. The adverse event had not resulted in doctor or other healthcare professional office/clinic visit/ emergency visit/ department or urgent care. The patient did not take any medication for headache, nausea, chills, fever, swollen arm, general body pain. The clinical outcome of the events headache, nausea, chills, fever, swollen arm, general body pain was recovering at the time of this report.   No follow-up attempts possible. No further information expected.
Age: 28.0
Sex: M
Vaccine: COVID19
Symptoms: Dizziness, Dyspnoea, Palpitations, Viral test
Clinical narrative: shortness of breath; dizziness; fast heart rate; This is a spontaneous report from a contactable consumer, a patient. A 28-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: ER8727) via an unspecified route of administration in right arm on 24Mar2021 at 15:15(at the age of 28-years-old), as a single dose for COVID-19 immunisation. The patients medical history included asthma and he had no known allergies. The concomitant medications included fluticasone propionate, salmeterol xinafoate (ADVAIR) for unknown indication from unknown date. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6205) via an unspecified route of administration in left arm on 03Mar2021 on 15:45(at the age of 28-years-old), as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 22Mar2021, the patient underwent the nasal swab and PCR test for the COVID-19 virus test and was tested negative. On 24Mar2021 at 17:00, the patient experienced shortness of breath, fast heartbeat and dizziness. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the events. The clinical outcome of the events shortness of breath, dizziness and heart racing was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.